Biosysen

Biosysen, founded in 2019 by Kang Kang and Jeffrey Yu, operates as a synthetic biology company from its headquarters in Shenzhen, China. The firm centers its operations on the concept of species design, utilizing software engineering principles to advance the biological industry. Biosysen's primary deliverable is a library of artificial species and associated industrial pipelines.

The company serves a diverse client base that includes developers in the food, medical testing, daily chemicals, and protein drug sectors. Its business model revolves around providing these clients with access to its proprietary library and industrial processes, aiming to create a comprehensive biotechnology ecosystem built on an artificial species architecture. This approach positions Biosysen within the specialty chemicals and database software industries, with a focus on artificial intelligence and machine learning applications.

Since its inception, Biosysen has secured funding through two venture capital rounds. The first occurred in July 2021, followed by a second angel round in July 2022. These funding rounds attracted several institutional investors, including Sequoia Capital China, Sky9 Capital, Linear Venture, Oasis Capital, Vitalbridge Capital, Hongshan Capital Group, and the accelerator Miracleplus. Keywords: synthetic biology, species design, artificial species library, industrial pipelines, biotechnology ecosystem, drug research, food development, medical testing, daily chemicals, protein drugs, software engineering concepts, biological industry, specialty chemicals, database software, AI in biology, machine learning in biotech, fermentation technology, bioprocessing, cell engineering, metabolic engineering